# Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

> **NCT00693706** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 200 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Trivalent influenza vaccine GSK 138842A
- **BIOLOGICAL:** Fluarix

## Key facts

- **NCT ID:** NCT00693706
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-02
- **Primary completion:** 2009-03-01
- **Final completion:** 2009-03-26
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693706, "Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00693706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*